Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...
 
 

Abecma: (idecabtagene vicleucel) A Newly Approved CAR-T Therapy for the Treatment of Multiple Myeloma and the Basics of Medicare Coverage


Date: Dec 10, 2021 12:00 PM - 01:30 PM

Fee

$0.00

CE Hours

1.50

CE Units

0.150

Registration closes on Feb 04, 2022 11:00 PM

Activity Type

  • Knowledge

Target Audience(s)

  • Pharmacists
  • Pharmacy Students
  • Residents
  • Fellows
  • Faculty

Accreditation(s)

Accreditation Council for Pharmacy Education
Accreditation Statement: Howard University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

 

 

 

   

Objectives

  • Identify the effects of myeloma cells in the diagnosis of multiple myeloma.
  • List the current FDA approved drug regimens used to treat multiple myeloma.
  • Identify the treatment challenges associated with treatment of multiple myeloma.
  • Explain the mechanism of action of idecabtagene vicleucel.

Speaker(s)/Author(s)

Cheryl Gilbreath
PharmD

Michel Okeke
Student Pharmacist

Activity Number

0010-0000-21-072-L01-P
Date: 12/10/21
Time: 12:00 PM - 01:30 PM

CE Hours

1.50